Nevro this week announced it enrolled the first patient in its painful diabetic neuropathy (PDN) sensory study. The prospective randomized controlled trial will assess the restoration of neurological function as a primary objective in patients with intractable PDN. It will enroll up to 236 patients at multiple sites across the U.S. Patients in the trial […]
Nevro Corp.
Nevro names Kevin Thornal as new CEO and president
Nervo (NYSE:NVRO) this week announced it appointed Kevin Thornal as CEO and president, effective April 24. Thornal succeeds D. Keith Grossman, who is retiring, also effective April 24. Grossman will be appointed to serve as executive chair of the company. “On behalf of the board and our entire company, I am excited to welcome Kevin […]
Nevro fully launches HFX iQ spinal cord stimulation
Nevro (NYSE:NVRO) announced today that it initiated the full U.S. market launch for its HFX iQ spinal cord stimulation (SCS) system. Redwood City, California–based Nevro designed HFX iQ for treating chronic pain. The company commenced its full launch after it completed a successful limited market release. In a news release, Dr. Usman Latif called HFX […]
Nevro announces CEO succession plan, preliminary Q4 results
Nevro (NYSE:NVRO) today announced that Chair, CEO and President D. Keith Grossman intends to retire this year. Grossman informed the board that he plans to retire from his CEO and president duties in 2023. He intends to do so following the selection of his successor at the spinal cord stimulation (SCS) technology developer. Following the […]
The biggest medtech stock gainers, losers in 2022
In another roller coaster year for medtech, these are the companies that saw their stock rise and fall the most drastically. The MassDevice MedTech 100 Index, which includes stocks of the world’s largest medical device companies, reflects the performance of many in the medtech space. In a tough year for a lot of businesses, the Index […]
FDA approves Nevro HFX iQ spinal cord stimulation
Nevro (NYSE:NVR) announced that the FDA approved its Senza HFX iQ spinal cord stimulation (SCS) system. Redwood City, California-based Nevro designed Senza HFX iQ to use artificial intelligence (AI) to learn from patients. The company says it’s the first such SCS system. It utilizes Nevro’s high-frequency 10 kHz therapy platform. The company developed it to […]
Nevro wins FDA approval for manufacturing operations in Costa Rica
Nevro (NYSE:NVRO) announced that the FDA approved manufacturing operations in Costa Rica for the production of its spinal cord stimulation (SCS) systems. Redwood City, Californa-based Nevro’s new facility sits in the Coyol Free Trade Zone in Alajuela, Costa Rica. It produces proprietary SCS systems that treat chronic pain, including the HFX product platform. The facility […]
Nevro wins multiple coverage options for spinal cord stimulation
Nevro (NYSE:NVRO) today announced positive updates to multiple spinal cord stimulation (SCS) coverage policies. Aetna’s new SCS policy explicitly covers PDN (painful diabetic neuropathy), effective Aug. 29, 2022. Aetna’s health plan covers approximately 22 million commercial lives. Novitas and First Coast, Medicare Administrative Contractors (MACs) that represent 12 states, also provided a positive update. They […]
Boston Scientific to pay Nevro $85M to settle rest of patent litigation
Nevro (NYSE:NVRO) and Boston Scientific (NYSE:BSX) announced today that they reached a settlement over intellectual property litigations. The settlement gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, with Nevro given the freedom to operate using the features and capabilities […]
Nevro rises on Street-beating Q4 sales
Nevro (NYSE:NVRO) shares ticked up today on fourth-quarter results that beat the consensus revenue forecast. The Redwood City, California-based company posted losses of $30.1 million, or -86¢ per share, on sales of $102.8 million for the three months ended Dec. 31, 2021, for a large bottom-line slide deeper into the red on a sales decline […]
Nevro touts 12-month data for 10 kHz spinal cord stimulation
Nevro (NYSE:NVRO) today reported positive 12-month data from the Senza-NSRBP randomized controlled trial of its implantable neurostimulation device for back pain. Redwood City, California–based Nevro’s data, published in Journal of Neurosurgery: Spine, showed that high-frequency 10 kHz spinal cord stimulation (SCS) therapy results in profound improvement in non-surgical refractory back pain (NSRBP) patients in comparison […]
